Alcoholic Hepatitis Network 3/9 University of Louisville
酒精性肝炎网络 3/9 路易斯维尔大学
基本信息
- 批准号:10434741
- 负责人:
- 金额:$ 34.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-08-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adrenal Cortex HormonesAlcoholic HepatitisAlcoholic Liver DiseasesAlcoholsBiological Specimen BanksClinicalClinical ResearchClinical TrialsClinical Trials DesignCollectionConduct Clinical TrialsConsumptionDataData Coordinating CenterData SetDatabasesDevelopmentDiseaseEconomic BurdenEducational workshopEligibility DeterminationFDA approvedFoundationsFundingFutureGoalsGranulocyte Colony-Stimulating FactorHepatitis BInfectionInflammasomeInflammationInformaticsInstitutionInterleukin-1 ReceptorsInterleukin-1 betaLabelLaboratoriesLifeLightLiteratureLiverLiver diseasesMedicalMissionMorbidity - disease rateNational Institute on Alcohol Abuse and AlcoholismObservational StudyOral cavityOutcomePathogenesisPatient CarePatient RecruitmentsPatientsPentoxifyllinePharmaceutical PreparationsPhasePilot ProjectsPositioning AttributePredispositionPrednisonePublic HealthRandomizedRecording of previous eventsResearch DesignResearch PersonnelResourcesRoleSamplingSeveritiesSystems BiologyTestingTherapeuticTherapeutic StudiesTranslational ResearchUniversitiesValidationWorkZincactive methodanakinraantagonistbasecatalystclinical centerdrug testingeffective therapyefficacy trialend stage liver diseaseevidence baseimprovedinsightinterestliver injurylongitudinal databasemeetingsmortalitynew therapeutic targetnovelprimary endpointprospectivereceptorresearch studysecondary endpointstandard of caretargeted treatmenttherapeutic developmenttherapeutically effectivetranslational studytreatment arm
项目摘要
ABSTRACT
Alcoholic hepatitis (AH) is a leading cause of liver-related morbidity and mortality with a remarkable paucity of
effective therapeutics. This application represents a coordinated submission of several NIAAA-funded
consortia that have come together as the Alcoholic Hepatitis Network (AlcHepNet). Collectively, the network
will synergize efforts and expertise to better understand AH and develop novel effective and safe therapies for
severe AH. Buttressing that goal, the overarching aims of this new consortium are to: 1) perform studies to
better understand the pathogenesis and main determinants of outcomes, particularly in severe AH; 2) identify
novel targets for therapy of AH, and 3) perform phase 2B studies of compounds that are already FDA
approved and available and can be repurposed as safe and effective therapies for severe AH. Under the
umbrella of these larger aims, the aims of this AlcHepNet proposal are to: Aim 1. Conduct a prospective,
multicenter, observational study of patients with AH and suitable controls that serves as the
foundation for conducting novel mechanistic and therapeutic studies. We will consolidate and extend our
longitudinal database containing 1) clinical and laboratory information and 2) bio-sample repository from
subjects with AH of varying severity and matched controls. This database will serve three functions: (a) provide
unique information on the outcomes and pathobiology of AH, (b) support translational research designed to
identify novel targets for treatment, and (c) serve as a catalyst to develop systems biology-based, informatics-
integrated databases that will serve as a resource for all researchers interested in AH; Aim 2. Perform a
multicenter, prospective, randomized phase 2B clinical trial of granulocyte colony stimulating factor G-
CSF versus Anakinra (plus zinc) versus standard medical therapy with Prednisone in patients with
severe AH. This aim will test the hypothesis that both active treatment arms with G-CSF and the IL-1 receptor
antagonist Anakinra (plus zinc) are superior to the standard of care (i.e. Prednisone) in patients with severe
AH. The choice of these agents is based on: 1) literature demonstrating a role for inflammation and
inflammasome activation in severe AH, 2) several pilot studies demonstrating therapeutic benefit with G-CSF,
and 3) interim analysis of an ongoing trial suggesting a mortality benefit with Anakinra in patients with AH. This
phase 2B efficacy trial will be conducted across nine clinical centers and coordinated by two Data Coordinating
Centers (DCCs). The primary endpoint will be mortality at Day 90. The investigators and the AlcHepNet are
uniquely positioned to perform the proposed study given the substantial breadth, depth, and history of
expertise related to AH, clinical trial conduct, and related therapeutic development. By testing promising
therapies for AH and collecting well-annotated patient samples and datasets, this proposal will have a strong
and lasting impact on the field.!
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CRAIG J. MCCLAIN其他文献
CRAIG J. MCCLAIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CRAIG J. MCCLAIN', 18)}}的其他基金
Inflammation Resolving Lipid Mediators: Novel Therapy for Alcohol AssociatedLiver Disease
消炎脂质介质:酒精相关性肝病的新疗法
- 批准号:
10590047 - 财政年份:2023
- 资助金额:
$ 34.96万 - 项目类别:
Administrative Supplement to Hepatobiology and Toxicology COBRE
肝生物学和毒理学 COBRE 行政增刊
- 批准号:
10399887 - 财政年份:2021
- 资助金额:
$ 34.96万 - 项目类别:
Alcoholic Hepatitis Network 3/9 University of Louisville
酒精性肝炎网络 3/9 路易斯维尔大学
- 批准号:
9752421 - 财政年份:2018
- 资助金额:
$ 34.96万 - 项目类别:
Alcoholic Hepatitis Network 3/9 University of Louisville
酒精性肝炎网络 3/9 路易斯维尔大学
- 批准号:
10202391 - 财政年份:2018
- 资助金额:
$ 34.96万 - 项目类别:
The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ Injury
营养在酒精引起的器官损伤的发生/进展中的作用
- 批准号:
10056411 - 财政年份:2016
- 资助金额:
$ 34.96万 - 项目类别:
相似海外基金
Biomarkers of Disease in Alcoholic Hepatitis Administrative Supplement
酒精性肝炎行政补充剂中疾病的生物标志物
- 批准号:
10840220 - 财政年份:2023
- 资助金额:
$ 34.96万 - 项目类别:
Evaluation of oral administration of PRIM-DJ2727 capsule containing microbiota suspension in patients with severe alcoholic hepatitis: An Open-Label Study
严重酒精性肝炎患者口服含有微生物悬浮液的 PRIM-DJ2727 胶囊的评价:一项开放标签研究
- 批准号:
10527603 - 财政年份:2022
- 资助金额:
$ 34.96万 - 项目类别:
Evaluation of oral administration of PRIM-DJ2727 capsule containing microbiota suspension in patients with severe alcoholic hepatitis: An Open-Label Study
严重酒精性肝炎患者口服含有微生物悬浮液的 PRIM-DJ2727 胶囊的评价:一项开放标签研究
- 批准号:
10686094 - 财政年份:2022
- 资助金额:
$ 34.96万 - 项目类别:
An innovative non-thiazolidinedione pan-PPAR agonist therapeutic for Alcoholic Hepatitis
一种创新的非噻唑烷二酮类泛 PPAR 激动剂,用于治疗酒精性肝炎
- 批准号:
10482468 - 财政年份:2022
- 资助金额:
$ 34.96万 - 项目类别:
Interactions between neutrophils and cholangiocytes in alcoholic hepatitis
酒精性肝炎中中性粒细胞和胆管细胞之间的相互作用
- 批准号:
10298412 - 财政年份:2021
- 资助金额:
$ 34.96万 - 项目类别:
Interactions between neutrophils and cholangiocytes in alcoholic hepatitis
酒精性肝炎中中性粒细胞和胆管细胞之间的相互作用
- 批准号:
10494268 - 财政年份:2021
- 资助金额:
$ 34.96万 - 项目类别:
Interactions between neutrophils and cholangiocytes in alcoholic hepatitis
酒精性肝炎中中性粒细胞和胆管细胞之间的相互作用
- 批准号:
10617893 - 财政年份:2021
- 资助金额:
$ 34.96万 - 项目类别:
Interactions between neutrophils and cholangiocytes in alcoholic hepatitis
酒精性肝炎中中性粒细胞和胆管细胞之间的相互作用
- 批准号:
10646369 - 财政年份:2021
- 资助金额:
$ 34.96万 - 项目类别:
Interactions between neutrophils and cholangiocytes in alcoholic hepatitis
酒精性肝炎中中性粒细胞和胆管细胞之间的相互作用
- 批准号:
10874892 - 财政年份:2021
- 资助金额:
$ 34.96万 - 项目类别: